The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
46
1. Three monthly intravitreal aflibercept (2mg) injections 2. Five bimonthly intravitreal aflibercept (2mg) injections 3. Rescue treatment: Verteporfin photodynamic therapy * Loss of five ETDRS letters or one Snellen line of vision from baseline * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection * Presence of active polyp on indocyanine green angiography
Seoul National University Bundang Hospital
Seongnam, Gyunggi-do, South Korea
Konyang University Kim's Eye Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Change of best-corrected visual acuity (ETDRS letters)
Time frame: 1 year
presence of subretinal hemorrhage
Total number of months when subretinal hemorrhage are detected on fundus photographs.
Time frame: during 1 year
presence of fluid in macula evidenced by optical coherence tomography
Total number of months when fluid in macula are detected on optical coherence tomography
Time frame: during 1 year
change of indocyanine green angiography
Change of indocyanine green angiography will include followings 1. New appearance of polypoidal structure 2. Any change in size of the greatest linear dimension of lesion 3. Any change in size and activity of branching vascular network
Time frame: during 1 year
Number of eyes which need rescue treatment (photodynamic therapy)
In this study, photodynamic therapy will be performed as a rescue therapy according to the necessary criteria.
Time frame: during 1 year
safety outcomes
frequency and severity of ocular adverse event
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.